Prostate Cancer - Results from #120

Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data. October 10, 2024

Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer. October 9, 2024

Plant-based diets and urological health. October 9, 2024

Nutrient Intakes in Prostate Cancer Survivors in the United States: A Nationally Representative Study. October 9, 2024

Comparative Transcriptomes of Canine and Human Prostate Cancers Identify Mediators of Castration Resistance. October 9, 2024

Quantitative MRI biomarker for classification of clinically significant prostate cancer: Calibration for reproducibility across echo times. October 9, 2024

Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer. October 9, 2024

Deep Learning Features Can Improve Radiomics-Based Prostate Cancer Aggressiveness Prediction. October 9, 2024

Synthetic Lethal Targeting of Cyclin Dependent Kinase-12-Deficient Prostate Cancer with PARP Inhibitors. October 9, 2024

Rediscovering citrate as a biomarker for prostate cancer. October 9, 2024

Unusual Prostate-Specific Membrane Antigen (PSMA) Splenic Uptake in a Patient With Prostate Cancer. October 8, 2024

Prostate cancer survivorship of Australian men living with prostate cancer: Patient support programs in Australia. October 8, 2024

Location-based Radiology Report-Guided Semi-supervised Learning for Prostate Cancer Detection. October 8, 2024

Patient Demographics and Major Adverse Cardiovascular Events after Androgen Deprivation Therapy for Prostate Cancer. October 8, 2024

Immediate Versus Delayed Exercise on Health-related Quality of Life in Patients Initiating Androgen Deprivation Therapy: Results from a Year-long Randomised Trial. October 8, 2024

ERLEADA® (Apalutamide) Demonstrates Statistically Significant and Clinically Meaningful Improvement in Overall Survival Compared to Enzalutamide in Patients with Metastatic Castration-Sensitive Prostate Cancer October 7, 2024

Single-Hit and Multi-hit PIK3CA Short Variant Genomic Alterations in Clinically Advanced Prostate Cancer: A Genomic Landscape Study. October 7, 2024

Creatine supplementation does not add to resistance training effects in prostate cancer patients under androgen deprivation therapy: A double-blind randomized trial. October 7, 2024

Health-related quality of life of patients with prostate cancer initiating GnRH agonist therapy: the PRISME study. October 7, 2024

CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13. October 7, 2024

Page 7 of 1435